（文章来源：证券日报） 证券日报网讯 2月2日，四方光电在互动平台回答投资者提问时表示，畅合生物目前暂无针对尼帕病毒 的专用检测方案。但畅合生物基于高效生物气溶胶富集与核酸扩增技术，已成功研发了生物气溶胶快速 检测监测产品及解决方案，可现场进行常见人畜病原的分析与风险预警，从而及时防控潜在传播风险。 ...

Group 1 - The company, YHLO (688575.SH), currently does not have any products related to Nipah virus testing [1] - YHLO specializes in respiratory infection immunity, particularly in Mycoplasma pneumoniae and EB virus, which are traditional projects for the company [1] - YHLO is the first domestic biotechnology company to apply chemiluminescence technology to serological testing for Mycoplasma pneumoniae and is one of the few domestic IVD suppliers capable of providing simultaneous IgG and IgM subtype testing for Mycoplasma pneumoniae and Chlamydia [1]

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Group 1 - The company Shanghai Laishi (002252.SZ) has stated that it currently does not have any products for Nipah virus testing [1] - There is no collaboration with Shanghai Institute of Pharmaceutical Industry at this time [1]

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

Core Viewpoint - The company currently does not have any Nipah virus-related testing reagents, instruments, or treatment drugs in its inventory, nor does it have any products for agency sales. The focus is on early identification and warning capabilities for high-risk acute infections through the Inflammatix TriVerity™ system, which can assist in early triage and monitoring for suspected cases of Nipah virus [1]. Group 1 - The company received an inquiry regarding its preparedness for the Nipah virus outbreak in West Bengal, India, which has affected several healthcare workers [1]. - The company confirmed that it does not possess any Nipah virus-related testing reagents or treatment options at this time [1]. - The company's strategic focus is on early identification and warning for high-risk acute infections, utilizing the Inflammatix TriVerity™ system for early infection type determination and risk stratification [1]. Group 2 - The Inflammatix TriVerity™ system can provide early warning and triage support in emergency settings for suspected cases, facilitating quicker diagnosis and treatment processes [1]. - The company emphasizes that while TriVerity™ can assist in early detection, final confirmation still requires pathogen detection methods [1].

Core Viewpoint - The company DaAn Gene has developed a comprehensive solution for Nipah virus pathogen detection, which can assist customs and disease control agencies in precise prevention and control efforts [2] Group 1: Product Offerings - DaAn Gene has recently launched the domestic small-scale rapid gene sequencer DAseq-60, which can be integrated with the Geno24 automated library preparation instrument, the viral whole genome detection reagent kit, and the pathogen intelligent analysis system to provide a complete clinical solution [2] - The second-generation sequencing solution enables the completion of whole genome sequencing of the Nipah virus, fulfilling various analytical needs such as mutation monitoring, typing tracing, and phylogenetic tree analysis, compared to traditional detection methods [2]

Core Viewpoint - The stock of Capbio has experienced a consecutive two-day limit-up, indicating strong market interest, particularly due to recent Nipah virus infection cases in Eastern India, which aligns with the company's product offerings in virus detection [1] Group 1: Stock Performance - Capbio's stock reached a limit-up at 13:08 today, with a trading volume of 1.275 billion yuan and a turnover rate of 24.53% [1] Group 2: Product and Market Position - The company possesses Nipah virus nucleic acid test kits, which are relevant for epidemic monitoring and border control [1] - As a leading integrated supplier of molecular diagnostic products and services in China, Capbio has developed products for infectious disease testing, covering clinical diagnosis in hospitals and public health prevention [1] Group 3: Research and Development - Capbio is advancing clinical research on HPV infection treatment, with international product deployment across multiple countries and regions [1] - The diversification of the company's business may enhance market attention and support its operations [1] Group 4: Market Trends - The virus prevention concept sector is gaining market attention, and changes in related demand may provide support for the company's business [1]

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].